行情

DRRX

DRRX

DURECT
NASDAQ

实时行情|Nasdaq Last Sale

1.940
+0.030
+1.57%
休市 16:00 11/15 EST
开盘
1.910
昨收
1.910
最高
1.950
最低
1.810
成交量
72.13万
成交额
--
52周最高
2.460
52周最低
0.4600
市值
3.73亿
市盈率(TTM)
-13.5286
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

DRRX 新闻

  • DURECT to Present at the Stifel 2019 Health Care Conference
  • PR Newswire.1天前
  • Edited Transcript of DRRX earnings conference call or presentation 4-Nov-19 9:30pm GMT
  • Thomson Reuters StreetEvents.3天前
  • AAP, SLDB among premarket losers
  • Seeking Alpha - Article.4天前
  • Durect Corporation Announces Results From Phase 2A Clinical Trial Of DUR-928 In Alcoholic Hepatitis Patients In A Late-breaking Presentation At The Liver Meeting; All Patients Treated With DUR-928 In Trial Survived 28-Day Follow-Up Period
  • Benzinga.4天前

更多

所属板块

生物技术和医学研究
+1.25%
制药与医学研究
+1.34%

热门股票

名称
价格
涨跌幅

DRRX 简况

Durect Corporation is a biopharmaceutical company with research and development programs. The Company's products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic. The Company's ALZET product line consists of miniature, implantable osmotic pumps and accessories used for experimental research in mice, rats and other laboratory animals. The Company also manufactures and sells osmotic pumps used in laboratory research and design; and develops and manufactures a range of standard and custom biodegradable polymers and excipients for pharmaceutical and medical device clients for use as raw materials in their products.
展开

Webull提供DURECT Corporation的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。